CEGX Back to portfolio


The TrueMethyl® Seq kit

Samples

DNA/protein in bar-coded sample tubes.

DNA

Nuclear transfer, pipette inserted into egg

Timeline

May 2012
Syncona meets with founders to review commercial opportunities for new method of sequencing novel base modification 5 hydroxymethyl cytosiine
August 2012
Syncona commits £500k in seed financing of the company
May 2016
Cambridge Epigenetix announces a $21m Series B investment by Google Ventures, Sequoia, New Science Ventures and Syncona

Company Details

Description

Research tools

Fully diluted ownership

12%

Value of Syncona holding

£5.2m

% of nav

0.6%

Description

CEGX is developing research tools which provide detailed resolution of epigenetic changes to DNA, a key piece of information which has clear research utility and clinical potential as a diagnostic tool for diseases such as cancer.

CEGX was Syncona’s first investment, made in 2012, and was formed out of the work of Professor Sir Shankar Balasubramanian, the co-inventor of the market leading sequencing platform now commercialised by Illumina Inc.

CEO

Jason Mellad

Syncona Representatives
  • Martin Murphy
Head of R&D
  • Toby Ost